Navigation Links
ACRG and BGI report new evidence for the genetic bases of liver cancer
Date:7/1/2013

July 1, 2013, Shenzhen, China The Asian Cancer Research Group (ACRG), an independent, not-for-profit company in collaboration with BGI, the world's largest genomics organization, and The University of Hong Kong (HKU), jointly announced the publication of findings from a study of recurrent mutations in hepatocellular carcinoma (HCC), one of the most deadly cancers worldwide, in the international journal Genome Research. The study provides new insights into potential therapeutic intervention strategies for this common form of liver cancer.

HCC is a primary malignancy of the hepatocytes, generally leading to death within 6-20 months after diagnosis. This type of cancer is more common in parts of Africa and Asia, where the patients with hepatitis B or C are at risk for liver cancer, even if they have not developed cirrhosis. HCC has limited treatment options such as surgical resection of the tumor at its early stage, and the molecular basis of its occurrence and development remains poorly understood.

In this study, researchers used whole genome sequencing (WGS) to survey a cohort of 88 matched HCC tumor and normal samples from Hong Kong for investigating alerted genes and the pathways implicated in HBV-associated HCC. They found that TP53 was the most commonly mutated tumor suppressor gene, accounting for 35.2% in the HCC cohort. Generally, the patients with tumors containing TP53 mutations exhibited poor survival.

The Wnt/β-Catenin signaling pathway is central for liver functions and is frequently abnormal activated in the carcinogenesis of HCC. Researchers in this study found β-catenin maybe the most frequently mutated oncogene. In addition to β-catenin, they found relative high mutation rates in genes in the JAK/STAT pathway, which may act as a major oncogenic driver in HCC tumor progression.

Hancheng Zheng, group leader of this project at BGI, said, "Liver cancer is intractable to nearly all currently available anti-cancer targeted therapies. Our findings in this study provide a better understanding of molecular basis of hepatocarcinogenesis and provide new clues to improving the diagnosis and treatment of liver cancer in the future."

"We detected a series of genes and pathways implicated in HBV-associated HCC using whole genome sequencing, which contribute to a better understanding of the tumor biology and targeted drug screening," said Dr. James Hardwick, Vice President of ACRG, and Director of Informatics & Analysis at Merck, "The ACRG was established to fuel research directed towards improving our understanding of cancers affecting Asian populations. By working together, we are able to generate important breakthroughs that can be transformed to better fight against liver cancer in the future."

"As clinicians, we are very excited about the several prevalent and actionable mutations identified from the study, including activating mutations of JAK1, which warrant testing several existing inhibitors for the treatment of the disease preclinically and clinically," said Dr. Ronnie Poon, Chair Professor and Chief, Division of Hepatobiliary and Pancreatic Surgery, The University of Hong Kong.


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. APS issues new policy requiring identification of sex or gender in reporting scientific research
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Researchers report potential for a moderate New England red tide in 2012
4. Aware, Inc. Reports First Quarter 2012 Financial Results
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. BGI reports the completed sequence of foxtail millet genome
7. Science reporters win ASM Public Communications Award
8. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
9. iView Systems iTrak® version 5.5 delivers optimized Incident Reporting
10. Report details efforts to improve, advance indoor microbial sampling
11. New report examines effects of trees killed by bark beetles on wildfire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... CHICAGO and FORT WORTH, Texas (PRWEB) , ... ... ... clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase ... Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... IntegritySM technology-based services specializing in background and medical screening, announces the launch ... planning and keeping their workforce safe. The new service is provided by ...
(Date:5/21/2020)... ... 2020 , ... Law Enforcement has always been a highly stressful career – ... of these men and women put them constantly in harm’s way both from the ... have always had to face very high daily stress. Now, COVID-19 introduces another even ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, the ... This includes buy three, get the fourth unit free with no limit on ... exosomes, known as exosomes, have been a game changer for regenerative therapies. The ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... I of a Small Business Innovation Research (SBIR) program funded by the National ... Rapid Toxin Detection in the Field”. The project’s goal was to engineer and ...
(Date:5/30/2020)... ... May 29, 2020 , ... Medrio, Inc., the leading provider ... has enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for ... first patient in (FPI) in just seven days. The Cytovale technology will allow ...
(Date:5/21/2020)... ... May 21, 2020 , ... Threats to intellectual property, political ... Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical ... from the pandemic commercially weaker, dealing with delays in new product launches and ...
Breaking Biology Technology: